{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T05:33:45Z","timestamp":1783229625382,"version":"3.54.6"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT) has shown promising results in preventing typhoid fever in children under 2 years of age. However, a thorough assessment of its safety and immunogenicity is required to inform vaccination strategies. This systematic review and meta-analysis aimed to determine the safety and immunogenicity of Vi-DT in children below 2\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched multiple databases, including PubMed, Web of Science, and Scopus, for relevant studies published up to September 2023. We included studies reporting on the safety and immunogenicity outcomes of Vi-DT compared to the control or Vi-tetanus toxoid conjugated vaccine (Vi-TT) in children below 2\u2009years. We applied a random-effects model for meta-analysis using RevMan 5.4. We expressed the results as risk ratio (RR) with a 95% confidence interval (95%CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this analysis, five studies were selected, encompassing 1,292 children under 2\u2009years who received the Vi-DT vaccine. No significant difference in immediate reactions was observed within 30\u2009min post-vaccination between Vi-DT and control groups (RR: 0.99 [95% CI: 0.19, 5.26]), nor between Vi-DT and Vi-TT groups. For solicited adverse events within 4\u2009weeks, the VI-DT group showed no significant increase in adverse events compared to control (RR: 0.93 [95% CI: 0.78, 1.12]) or Vi-TT (RR: 0.86 [95% CI: 0.69, 1.07]). Similarly, within 7\u2009days post-vaccination, risk ratios indicated no significant differences in adverse events between the groups. The 4-week seroconversion rate was significantly higher in the Vi-DT group compared to the control (RR: 1.99 [95% CI: 1.07, 3.69]), but no difference was found between Vi-DT and Vi-TT. Adverse events associated with typhoid conjugate vaccines were predominantly non-serious, including fever and injection site reactions. Serious adverse events were rare but included conditions like pneumonia and gastroenteritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis highlights Vi-DT safety and immunogenicity in six to 24-month-old children. The findings support the use of this Vi-DT to expand typhoid vaccination in endemic regions, in line with WHO\u2019s strategy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2024.1385834","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:59:37Z","timestamp":1712293177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2\u2009years: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Amira","family":"Mohamed Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abouelmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman Mohamed","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hamouda","family":"Elkasaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Katterine","family":"Bonilla-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Rodriguez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.15167\/2421-4248\/jpmh2017.58.1.747","article-title":"Overview of the impact of typhoid and paratyphoid fever. Utility of Ty21a vaccine (Vivotif\u00ae)","volume":"58","author":"Amicizia","year":"2017","journal-title":"J. Prev. Med. Hyg."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/bmj.316.7144.1571","article-title":"Science commentary: why conjugate vaccines protect longer","volume":"316","author":"Berger","year":"1998","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3201\/eid1102.040422","article-title":"Bacteremic typhoid fever in children in an urban slum, Bangladesh","volume":"11","author":"Brooks","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S1473-3099(18)30087-2","article-title":"Typhoid conjugate vaccine gets WHO prequalification","volume":"18","author":"Burki","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100540","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.lanwpc.2022.100484","article-title":"A phase 3, multicenter, randomized, controlled trial to evaluate immune equivalence and safety of multidose and single-dose formulations of vi-DT typhoid conjugate vaccine in healthy Filipino individuals 6 months to 45 years of age","volume":"24","author":"Carlos","year":"2022","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2203634","DOI":"10.1080\/21645515.2023.2203634","article-title":"A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of vi-diphtheria toxoid versus vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal","volume":"19","author":"Chaudhary","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref9","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/649541","article-title":"Global trends in typhoid and paratyphoid fever","volume":"50","author":"Crump","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e0004597","DOI":"10.1371\/journal.pntd.0004597","article-title":"Enteric fever: a slow response to an old plague","volume":"10","author":"Franco-Paredes","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/infdis\/173.6.1408","article-title":"phoP\/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers","volume":"173","author":"Hohmann","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1093\/cid\/ciy1118","article-title":"Accelerating typhoid conjugate vaccine introduction: what can be learned from prior new vaccine introduction initiatives?","volume":"68","author":"Jamka","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/cid\/ciy386","article-title":"Determining the best immunization strategy for protecting African children against invasive Salmonella disease","volume":"67","author":"Jeon","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/microorganisms9071394","article-title":"A Salmonella Typhi controlled human infection study for assessing correlation between bactericidal antibodies and protection against infection induced by typhoid vaccination","volume":"9","author":"Jones","year":"2021","journal-title":"Microorganisms"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1128\/iai.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infect. Immun."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(87)90480-6","article-title":"Large-scale field trial of ty21a live oral typhoid vaccine in enteric-coated capsule formulation","volume":"329","author":"Levine","year":"1987","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"101946","DOI":"10.1016\/j.tmaid.2020.101946","article-title":"Typhoid fever infection \u2013 antibiotic resistance and vaccination strategies: a narrative review","volume":"40","author":"Masuet-Aumatell","year":"2021","journal-title":"Travel Med. Infect. Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0890-6238(94)90015-9","article-title":"Oral typhoid vaccine and pregnancy","volume":"8","author":"Mazzone","year":"1994","journal-title":"Reprod. Toxicol. Elmsford N"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2020.01.045","article-title":"One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of vi-DT typhoid conjugate vaccine","volume":"93","author":"Medise","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0211784","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomised clinical trial-phase I study in Indonesian adults and children: safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a vi polysaccharide\u2013tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1093\/cid\/ciy1124","article-title":"Epidemiology of typhoid and paratyphoid: implications for vaccine policy","volume":"68","author":"Saha","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref29","year":"2023"},{"key":"ref30","year":"2023"},{"key":"ref31","year":"2023"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, march 2018 \u2013 recommendations","volume":"37","year":"2019","journal-title":"Vaccine"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1385834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:59:40Z","timestamp":1712293180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1385834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":32,"alternative-id":["10.3389\/fmicb.2024.1385834"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1385834","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1385834"}}